Targeting Graft Versus Host Disease in Bone Marrow Transplants
Precision Alemtuzumab Therapy in Allogeneic HCT
This study is looking at how a medicine called alemtuzumab can help kids and young adults who are getting a special type of transplant to avoid problems like graft rejection and graft versus host disease, and it aims to find the best dose to help them recover better and live longer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cincinnati Childrens Hosp Med Ctr NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-10890713 on NIH RePORTER |
What this research studies
This research focuses on improving the treatment of pediatric and young adult patients undergoing allogeneic hematopoietic cell transplantation (HCT) for various serious conditions. It investigates the use of alemtuzumab, a monoclonal antibody, to prevent complications such as graft rejection and graft versus host disease (GVHD). The study aims to determine the optimal dosing of alemtuzumab to enhance patient outcomes and survival rates. By carefully monitoring drug levels, the research seeks to ensure that patients receive the most effective treatment during their transplant process.
Who could benefit from this research
Good fit: Ideal candidates for this research are pediatric and young adult patients requiring allogeneic HCT for conditions like severe inborn errors of immunity or hematologic disorders.
Not a fit: Patients who are not undergoing allogeneic HCT or those with conditions not addressed by this treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better management of graft versus host disease, improving survival rates and quality of life for patients undergoing bone marrow transplants.
How similar studies have performed: Previous research has shown promising results with alemtuzumab in similar contexts, indicating potential for success in this approach.
Where this research is happening
Cincinnati, United States
- Cincinnati Childrens Hosp Med Ctr — Cincinnati, United States (Active)
Researchers
- Principal investigator: Mehta, Parinda a. — Cincinnati Childrens Hosp Med Ctr
- Study coordinator: Mehta, Parinda a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.